Literature DB >> 16375648

Aurora A and B kinases as targets for cancer: will they be selective for tumors?

Nick Matthews1, Cristina Visintin, Basil Hartzoulakis, Ashley Jarvis, David L Selwood.   

Abstract

Aurora A and B kinases are closely related kinases involved in regulating separate points in the cell cycle. This review highlights the rationale for Aurora kinases as cancer targets and examines the currently known Aurora kinase inhibitors in the patent and scientific literature. The known crystal structures of the Aurora kinases are described with relevance to bound ligand interactions and the prospect of the generation of drug-resistant mutant forms. The potential for selectivity versus primary cells will also be discussed. The status of the inhibitors in clinical development is described.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16375648     DOI: 10.1586/14737140.6.1.109

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  15 in total

1.  Recognizing and exploiting differences between RNAi and small-molecule inhibitors.

Authors:  William A Weiss; Stephen S Taylor; Kevan M Shokat
Journal:  Nat Chem Biol       Date:  2007-12       Impact factor: 15.040

Review 2.  Target validation and biomarker identification in oncology : the example of aurora kinases.

Authors:  Riccardo Colombo; Jürgen Moll
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 3.  The future of small molecule inhibitors in lymphoma.

Authors:  John Gerecitano
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

Review 4.  Cell cycle kinases as therapeutic targets for cancer.

Authors:  Silvia Lapenna; Antonio Giordano
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

5.  Structural studies of B-type Aurora kinase inhibitors using computational methods.

Authors:  Mm Neaz; M Muddassar; Fa Pasha; Seung Joo Cho
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

6.  Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.

Authors:  Arati Sharma; SubbaRao V Madhunapantula; Raghavendra Gowda; Arthur Berg; Rogerio I Neves; Gavin P Robertson
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

7.  Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition.

Authors:  Linda Vidarsdottir; Gudridur Steingrimsdottir; Sigridur Klara Bodvarsdottir; Helga Margret Ogmundsdottir; Jorunn Erla Eyfjord
Journal:  Invest New Drugs       Date:  2010-10-20       Impact factor: 3.850

8.  The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms.

Authors:  Neal Jetton; Karen G Rothberg; James G Hubbard; John Wise; Yan Li; Haydn L Ball; Larry Ruben
Journal:  Mol Microbiol       Date:  2009-03-06       Impact factor: 3.501

9.  A current review of targeted therapeutics for ovarian cancer.

Authors:  Susana M Campos; Sue Ghosh
Journal:  J Oncol       Date:  2010-01-03       Impact factor: 4.375

10.  Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Authors:  Yvonne G Lin; Anand Immaneni; William M Merritt; Lingegowda S Mangala; Seung Wook Kim; Mian M K Shahzad; Yvonne T M Tsang; Guillermo N Armaiz-Pena; Chunhua Lu; Aparna A Kamat; Liz Y Han; Whitney A Spannuth; Alpa M Nick; Charles N Landen; Kwong K Wong; Michael J Gray; Robert L Coleman; Diane C Bodurka; William R Brinkley; Anil K Sood
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.